Charter Medical Announces Dana-Farber Cancer Institute Approves Cell-Freeze(r) for Stem Cell Cryopreservation

WINSTON-SALEM, N.C., June 23, 2009 (GLOBE NEWSWIRE) -- Charter Medical, Ltd., a division of Lydall, Inc. (NYSE:LDL), is pleased to announce today that their 501(k) cleared CELL-FREEZE(r) cryogenic storage containers were approved by Dana-Farber Cancer Institute in Boston, MA. CELL-FREEZE(r) was designed for peripherally derived stem cells and used for cryogenic temperature applications as low as -196 degrees Celsius for storage, preservation and transfer. Dana-Farber Cancer Institute, a national leader in adult and pediatric cancer care and research, will be using CELL-FREEZE(r) for stem cell applications.

Back to news